15 January 2026
This week at the J.P. Morgan Healthcare Conference, my message to our customers, partners, and investors was clear: 2026 will be a revolutionary year for precision health, and Illumina will lead that revolution.
Our goal is to enable a transformative precision health ecosystem—one fueled by historic advances in genomics, multiomics, data, and AI.
To that end, we unveiled our Billion Cell Atlas, which uses AI to push drug discovery into hyperscale territory, mapping out biological pathways behind some of the world’s most devastating diseases.
We’re proud to partner with AstraZeneca, Eli Lilly, and Merck, who will be the first to use the Atlas to validate genetic targets and train AI models at an unprecedented scale.
This is a major proof point of our BioInsight business strategy—creating datasets that can reinvent drug development pipelines.
The data and AI opportunity
As ‘omic’ data proliferates, data and AI are vital to advance our understanding of human biology and disease, driving our commitment to be the leading platform for life sciences intelligence. Our customers and investors are watching these trends because they know the ability to analyze and interpret vast amounts of biologic data will drive the next era of precision health—and the breakthrough treatments of the future.
The proliferation of data fueling discovery is driven in part by the scale we have introduced in multiomics—taking the industry beyond genomics to achieve a deeper understanding of biology.
Multiomics
By year’s end, our portfolio of complete multiomic solutions will be available to every customer, including streamlined data analysis via the unmatched Illumina Connected Multiomics. We are the only company that can offer this comprehensive set of solutions, enabled on our core platforms.
Across genomics, proteomics, transcriptomics, and epigenomics, each ome tells us something distinct about biology. Researchers and clinicians need this complete view across complex biological data to better understand, diagnose, treat, and prevent disease.
We also look forward to fully launching our constellation mapped-read technology, which is redefining what’s possible with short-read sequencing and showing incredible promise in solving critical challenges in rare disease.
All these transformative capabilities will be available on the NovaSeq X, delivering sustainable value and continued innovation for customers through a single platform.
Clinical access
We are also doubling down on our clinical strategy.
Over the past year, clinical adoption of Illumina next-generation sequencing solutions grew steadily, thanks to new assays coming to market, positive reimbursement decisions, and a growing need for more sequencing-intensive applications like minimal residual disease (MRD) testing and comprehensive genomic profiling (CGP).
We recently welcomed Eric Green, MD, PhD, as our new chief medical officer. His leadership will be essential as we accelerate frameworks for equitable access to critical testing and precision therapies for hospitals and health systems at every level around the world.
By empowering genomic testing closer to the point of care across the health ecosystem, Illumina is driving the transition from sick care to health care.
Our suite of software, informatics, and AI solutions accelerate the pace of discovery and empower pharma partners and our customers to uncover answers to the most complex biological questions.
Through BioInsight, we’re bridging the gap between masses of data and actionable insights. We’re also building the next generation of AI models—enabling breakthroughs in disease diagnosis, drug discovery, and precision medicine.
You know Illumina as a sequencing tools provider. But we are evolving rapidly. With sequencing as our foundation, advanced AI and massive biological data are converging to transform our understanding of human biology and disease.
This year will be about deep partnership and unparalleled innovation to expand the boundaries of discovery. We are redefining what’s possible. And we’re just getting started.
